Eye on Ozempic: FDA forces blindness-risk warning onto weight-loss jabs
Reuters, via CNN, reports the FDA told patients and providers of a possible increased risk of a serious eye condition tied to GLP-1 drugs. The agency is requiring makers of drugs including Ozempic, Wegovy, Mounjaro and Zepbound to add non-arteritic anterior ischemic optic neuropathy (NAION) to the warnings section of their labels. NAION is a common cause of sudden, painless vision loss and can be permanent. Last year, European regulators said it may affect up to 1 in 10,000 semaglutide users.
From cnn.com's report.
Why it matters: Millions taking GLP-1 drugs like Ozempic, Wegovy, Mounjaro and Zepbound will see a new label warning about a possible risk of sudden, sometimes permanent vision loss, which patients and doctors may weigh when choosing treatment.
Comments
No comments yet.